Related Experiment Video
Updated: Aug 17, 2026

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
Published on: February 1, 2018
Parenteral beta-lactamase inhibitor combinations for clinical use
1Department of Family Medicine, York Hospital, Pa., USA.
Abstract:
Beta-lactamase enzymes are commonly produced by staphylococci, the Enterobacteriaceae, Pseudomonas aeruginosa and certain anaerobic organisms, such as Bacteroides fragilis. The production of beta lactamases is an important mechanism through which bacteria become resistant to antibiotics. The currently marketed beta-lactamase inhibitor combinations include ampicillin-sulbactam, ticarcillin-clavulanate potassium and, more recently, piperacillin-tazobactam. These extended spectrum antibiotic combinations share the ability to inhibit methicillin-susceptible staphylococci, nearly all anaerobic bacteria and many Enterobacteriaceae. Ticarcillin-clavulanate potassium and piperacillin-tazobactam also have activity against P. aeruginosa. The combination agents are useful in the treatment of moderate to severe infections, particularly when a polymicrobial etiology is suspected or documented.
More Related Videos
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Production of Antibiotics
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance

